Brokerages Set GSK plc (LON:GSK) Target Price at GBX 1,829.17

Shares of GSK plc (LON:GSK) have been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is GBX 1,839.29.

A number of research firms have weighed in on GSK. Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Thursday, January 8th. Citigroup reiterated a “buy” rating and set a GBX 1,900 target price on shares of GSK in a research report on Tuesday. UBS Group reissued a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft lifted their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a report on Thursday, January 15th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th.

GSK Price Performance

LON GSK opened at GBX 1,862.50 on Friday. GSK has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 1,909.73. The company has a fifty day simple moving average of GBX 1,819.46 and a 200 day simple moving average of GBX 1,638.89. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The company has a market cap of £75.14 billion, a P/E ratio of 14.00, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, sell-side analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In other GSK news, insider Jonathan Symonds purchased 1,650 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was acquired at an average cost of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker purchased 441 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was bought at an average cost of GBX 1,809 per share, with a total value of £7,977.69. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.